Loading stock data…
Clene Inc (CLNN)
$6.33+0.28 (+4.54%)
Market ClosedLast close Jun 29
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Clene Inc. in the Consumer Defensive sector is trading at $6.33 with a market capitalization of $71M. Wall Street consensus targets $32.20 (5 analysts), implying a +408.3% move over the next 12 months. The stock is currently 53% below its 52-week high of $13.50, remaining 3.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 78 is overbought against a weak tape. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +408.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 78 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15,000↓ | $77,000↑ | $15,000↓ | $27,000↓ | $81,000 |
| Gross Profit | $15,000↓ | $54,000↑ | $15,000↓ | $27,000↓ | $61,000 |
| Operating Income | -$1.69M↑ | -$7.24M↓ | -$5.37M↑ | -$5.63M↓ | -$3.57M |
| Net Income | -$8.09M↑ | -$9.23M↓ | -$8.78M↓ | -$7.42M↓ | -$751,000 |
Peer Comparison
Fundamentals
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in vario...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$70.79M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
178.20%
Volume
Today's trading volume
106,047
Recent News
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Clene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
3 Growth Stocks Insiders Are Betting On
In the last week, the United States market has stayed flat, yet it is up 24% over the past year, with earnings expected to grow by 17% per annum over the next few years. In this environment, stocks with strong growth potential and high insider ownership can be particularly appealing as they may indicate confidence from those most familiar with the company's prospects.